Corrigendum : CD1d-invariant natural killer T cell-based cancer immunotherapy: α-galactosylceramide and beyond (Frontiers in Immunology (2018) 9 (1519) DOI: 10.3389/fimmu.2018.01519)

Research output: Contribution to journalErratumAcademicpeer-review

Abstract

by King, L. A., Lameris, R., de Gruijl, T. D., and van der Vliet, H. J. (2018). Front. Immunol. 9:1519. doi: 10.3389/fimmu.2018.01519 In the original article, we neglected to disclose that authors Lisa A. King and Roeland Lameris are currently funded by Lava Therapeutics and that Hans J. van der Vliet also acts as chief scientific officer of Lava Therapeutics. Hans J. van der Vliet's affiliation has been updated to reflect this. The corrected Conflict of Interest statement appears below.
Original languageEnglish
Article number2606
JournalFrontiers in Immunology
Volume9
Issue numberNOV
DOIs
Publication statusPublished - 2018

Cite this

@article{6b45c5b90bab44e584f2d54fa8a95159,
title = "Corrigendum : CD1d-invariant natural killer T cell-based cancer immunotherapy: α-galactosylceramide and beyond (Frontiers in Immunology (2018) 9 (1519) DOI: 10.3389/fimmu.2018.01519)",
abstract = "by King, L. A., Lameris, R., de Gruijl, T. D., and van der Vliet, H. J. (2018). Front. Immunol. 9:1519. doi: 10.3389/fimmu.2018.01519 In the original article, we neglected to disclose that authors Lisa A. King and Roeland Lameris are currently funded by Lava Therapeutics and that Hans J. van der Vliet also acts as chief scientific officer of Lava Therapeutics. Hans J. van der Vliet's affiliation has been updated to reflect this. The corrected Conflict of Interest statement appears below.",
author = "King, {Lisa A.} and Roeland Lameris and {de Gruijl}, {Tanja D.} and {van der Vliet}, {Hans J.}",
year = "2018",
doi = "10.3389/fimmu.2018.02606",
language = "English",
volume = "9",
journal = "Frontiers in Immunology: Molecular Innate Immunity",
issn = "1664-3224",
publisher = "Frontiers Media S.A.",
number = "NOV",

}

TY - JOUR

T1 - Corrigendum : CD1d-invariant natural killer T cell-based cancer immunotherapy: α-galactosylceramide and beyond (Frontiers in Immunology (2018) 9 (1519) DOI: 10.3389/fimmu.2018.01519)

AU - King, Lisa A.

AU - Lameris, Roeland

AU - de Gruijl, Tanja D.

AU - van der Vliet, Hans J.

PY - 2018

Y1 - 2018

N2 - by King, L. A., Lameris, R., de Gruijl, T. D., and van der Vliet, H. J. (2018). Front. Immunol. 9:1519. doi: 10.3389/fimmu.2018.01519 In the original article, we neglected to disclose that authors Lisa A. King and Roeland Lameris are currently funded by Lava Therapeutics and that Hans J. van der Vliet also acts as chief scientific officer of Lava Therapeutics. Hans J. van der Vliet's affiliation has been updated to reflect this. The corrected Conflict of Interest statement appears below.

AB - by King, L. A., Lameris, R., de Gruijl, T. D., and van der Vliet, H. J. (2018). Front. Immunol. 9:1519. doi: 10.3389/fimmu.2018.01519 In the original article, we neglected to disclose that authors Lisa A. King and Roeland Lameris are currently funded by Lava Therapeutics and that Hans J. van der Vliet also acts as chief scientific officer of Lava Therapeutics. Hans J. van der Vliet's affiliation has been updated to reflect this. The corrected Conflict of Interest statement appears below.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85057431281&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30519237

U2 - 10.3389/fimmu.2018.02606

DO - 10.3389/fimmu.2018.02606

M3 - Erratum

VL - 9

JO - Frontiers in Immunology: Molecular Innate Immunity

JF - Frontiers in Immunology: Molecular Innate Immunity

SN - 1664-3224

IS - NOV

M1 - 2606

ER -